Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells $439,752.00 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the sale, the chief marketing officer now owns 15,705 shares of the company’s stock, valued at approximately $3,941,955. This represents a 10.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pushkal Garg also recently made the following trade(s):

• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $245.44 on Monday. The firm has a market capitalization of $31.66 billion, a price-to-earnings ratio of -93.68 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The business has a fifty day simple moving average of $267.01 and a 200 day simple moving average of $249.57. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The business’s quarterly revenue was down 33.3% on a year-over-year basis. During the same period last year, the company posted $1.15 EPS. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Huntington National Bank grew its stake in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management bought a new stake in Alnylam Pharmaceuticals in the third quarter valued at $29,000. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter worth $26,000. Washington Trust Advisors Inc. bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at $42,000. Finally, True Wealth Design LLC boosted its stake in shares of Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on ALNY. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Bank of America increased their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th. Raymond James boosted their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Piper Sandler restated an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.